Amneal Pharmaceuticals (AMRX) Stock Forecast, Price Target & Predictions
AMRX Stock Forecast
Amneal Pharmaceuticals (AMRX) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $9.50, with a high of $12.00 and a low of $4.00. This represents a -5.85% decline from the last price of $10.09.
AMRX Stock Rating
Amneal Pharmaceuticals stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (62.50%), 6 Hold (37.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).
Buy
AMRX Price Target Upside V Benchmarks
Type | Name | Upside |
---|---|---|
Stock | Amneal Pharmaceuticals | -5.85% |
Sector | Healthcare Stocks | 13.55% |
Industry | Specialty & Generic Drug Manufacturers Stocks | 17.30% |
Price Target Trends
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 4 |
Avg Price Target | - | - | $11.00 |
Last Closing Price | $10.09 | $10.09 | $10.09 |
Upside/Downside | - | - | 9.02% |
Ratings Trends
Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
---|---|---|---|---|---|---|
Sep, 25 | 2 | 2 | - | - | - | 4 |
Aug, 25 | 2 | 2 | - | - | - | 4 |
Jul, 25 | 3 | 1 | - | - | - | 4 |
Jun, 25 | 2 | 1 | - | - | - | 3 |
May, 25 | 2 | 1 | - | - | - | 3 |
Analyst Price Target Forecasts
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Mar 03, 2025 | Barclays | $11.00 | $8.76 | 25.57% | 9.02% | |
Nov 11, 2024 | David Amsellem | Piper Sandler | $11.00 | $8.29 | 32.69% | 9.02% |
Oct 02, 2024 | Les Sulewski | Truist Financial | $12.00 | $8.70 | 37.93% | 18.93% |
Oct 01, 2024 | Les Sulewski | Truist Financial | $10.00 | $8.70 | 14.94% | -0.89% |
May 03, 2024 | Les Sulewski | Truist Financial | $9.00 | $6.76 | 33.14% | -10.80% |
Mar 21, 2024 | David Amsellem | Piper Sandler | $8.00 | $6.29 | 27.19% | -20.71% |
Aug 08, 2022 | Goldman Sachs | $4.00 | $3.22 | 24.22% | -60.36% |
Analyst Rating Forecasts
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Mar 03, 2025 | Barclays | Overweight | Overweight | hold |
Nov 11, 2024 | Piper Sandler | Overweight | Overweight | hold |
Aug 13, 2024 | Barclays | Overweight | Overweight | hold |
Aug 08, 2022 | Goldman Sachs | Buy | Buy | hold |
Financial Forecast
EPS Forecast
Annual
Dec 20 | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Dec 26 | |
---|---|---|---|---|---|---|
Reported | $0.47 | $-1.69 | $-0.48 | $-0.38 | - | - |
Avg Forecast | $0.37 | $0.70 | $0.57 | $0.61 | $0.70 | - |
High Forecast | $0.44 | $0.84 | $0.58 | $0.62 | $0.79 | - |
Low Forecast | $0.29 | $0.55 | $0.56 | $0.60 | $0.58 | - |
Surprise % | 27.03% | -341.43% | -184.21% | -162.30% | - | - |
Revenue Forecast
Annual
Dec 20 | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Dec 26 | |
---|---|---|---|---|---|---|
Reported | $1.99B | $2.21B | $2.39B | $2.79B | - | - |
Avg Forecast | $1.80B | $2.23B | $2.41B | $2.77B | $2.90B | $3.06B |
High Forecast | $2.16B | $2.68B | $2.46B | $2.83B | $2.96B | $3.13B |
Low Forecast | $1.44B | $1.79B | $2.40B | $2.73B | $2.86B | $3.02B |
Surprise % | 10.82% | -0.89% | -0.68% | 0.86% | - | - |
Net Income Forecast
Annual
Dec 20 | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Dec 26 | |
---|---|---|---|---|---|---|
Reported | $68.58M | $-254.79M | $-83.99M | $-116.89M | - | - |
Avg Forecast | $73.24M | $-131.13M | $-83.99M | $107.44M | $120.65M | - |
High Forecast | $94.86M | $-104.90M | $-67.19M | $109.20M | $139.15M | - |
Low Forecast | $51.63M | $-157.36M | $-100.79M | $105.68M | $102.16M | - |
Surprise % | -6.37% | 94.30% | - | -208.79% | - | - |